3-(5-chloro-2-hydroxy-phenyl)-propionic acid | 749878-89-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(5-chloro-2-hydroxy-phenyl)-propionic acid
• 英文别名: 3-(5-Chlor-2-hydroxy-phenyl)-propionsaeure；β-(5-Chlor-2-oxy-phenyl)-propionsaeure；5-Chlor-2-oxy-hydrozimtsaeure；5-Chlor-hydro-o-cumarsaeure；5-Chlor-2-hydroxyphenyl-1-propionsaeure；3-(5-Chloro-2-hydroxyphenyl)propanoic acid
• CAS: 749878-89-5
• 化学式: C₉H₉ClO₃
• 分子量: 200.622
• InChiKey: ONNIBDHZMCXKPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(5-chloro-2-hydroxy-phenyl)-propionic acid 生成 6-氯苯并二氢吡喃-2-酮
  参考文献：
  名称：

  DE386619

  摘要：

  公开号：
• 作为产物：
  描述：

  (5-chloro-2-methoxy-benzyl)-malononitrile 在 氢溴酸 作用下， 生成 3-(5-chloro-2-hydroxy-phenyl)-propionic acid
  参考文献：
  名称：

  Vinylidene Cyanide. V. The Aluminum Chloride Catalyzed Reaction of Vinylidene Cyanide and Aromatic Compounds

  摘要：

  DOI：

  10.1021/ja01633a043

文献信息

• Use of an inducing agent for the treatment of blood, viral and cellular disorders
  申请人：Perrine, Susan P.

  公开号：EP1611885A1

  公开（公告）日：2006-01-04

  The invention relates to novel compositions and to novel methods for the administration of compositions to a patient or to cells in vitro for the treatment of human disorders. In one embodiment, compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia and other blood disorders. In another embodiment, compositions contain an inducing agent and an anti-viral agent. The inducing agent induces the expression of a cellular or viral product, such as viral thymidine kinase, increasing the sensitivity of proliferating cells to the anti-viral agent. Typical anti-viral agents include nucleoside analogs such as ganciclovir that inhibit viral replication. Methods involve administration of therapeutically effective amounts of the inducing agent with the anti-viral agent to destroy virus-infected cells. Viral infections that can be treated include infections by herpes viruses such as Kaposi's-associated herpes virus and Epstein-Barr virus, HIV infections and HTLV infections. These compositions and methods are particularly effective against episomal and latent infections in proliferating cells. The invention also relates to novel methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies such as viral-induced tumors, other forms of neoplasia and for expansion of cells for hematopoietic transplantation.

  本发明涉及治疗人类疾病的新型组合物和向患者或体外细胞施用组合物的新型方法。在一个实施方案中，组合物含有刺激胎儿血红蛋白表达和/或刺激患者体内和体外红细胞、白细胞和血小板增殖以重建体内造血的化合物。这些方法可用于治疗或预防贫血、镰状细胞病、地中海贫血和其他血液疾病的相关症状。在另一个实施方案中，组合物含有一种诱导剂和一种抗病毒剂。诱导剂可诱导细胞或病毒产物（如病毒胸苷激酶）的表达，增加增殖细胞对抗病毒剂的敏感性。典型的抗病毒剂包括核苷类似物，如更昔洛韦，可抑制病毒复制。方法是将治疗有效量的诱导剂与抗病毒剂一起施用，以消灭受病毒感染的细胞。可治疗的病毒感染包括疱疹病毒感染，如卡波济氏相关疱疹病毒和 Epstein-Barr 病毒、HIV 感染和 HTLV 感染。这些组合物和方法对增殖细胞中的表观感染和潜伏感染特别有效。本发明还涉及向患者脉冲式施用组合物的新方法，用于治疗和预防细胞增殖性疾病，包括细胞减少症等缺陷和病毒引起的肿瘤等恶性肿瘤、其他形式的肿瘤以及用于造血移植的细胞扩增。
• Composition comprising an inducing agent and an anti-viral agent for the treatment of viral disorders
  申请人：Perrine, Susan P.

  公开号：EP2298350A2

  公开（公告）日：2011-03-23

  The invention relates to novel compositions and to novel methods for the administration of compositions to a patient or to cells in vitro for the treatment of human disorders. In one embodiment, compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia and other blood disorders. In another embodiment, compositions contain an inducing agent and an anti-viral agent. The inducing agent induces the expression of a cellular or viral product, such as viral thymidine kinase, increasing the sensitivity of proliferating cells to the anti-viral agent. Typical anti-viral agents include nucleoside analogs such as ganciclovir that inhibit viral replication. Methods involve administration of therapeutically effective amounts of the inducing agent with the anti-viral agent to destroy virus-infected cells. Viral infections that can be treated include infections by herpes viruses such as Kaposi's-associated herpes virus and Epstein-Barr virus, HIV infections and HTLV infections. These compositions and methods are particularly effective against episomal and latent infections in proliferating cells. The invention also relates to novel methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies such as viral-induced tumors, other forms of neoplasia and for expansion of cells for hematopoietic transplantation.

  本发明涉及治疗人类疾病的新型组合物和向患者或体外细胞施用组合物的新型方法。在一个实施方案中，组合物含有刺激胎儿血红蛋白表达和/或刺激患者体内和体外红细胞、白细胞和血小板增殖以重建体内造血的化合物。这些方法可用于治疗或预防贫血、镰状细胞病、地中海贫血和其他血液疾病的相关症状。在另一个实施方案中，组合物含有一种诱导剂和一种抗病毒剂。诱导剂可诱导细胞或病毒产物（如病毒胸苷激酶）的表达，增加增殖细胞对抗病毒剂的敏感性。典型的抗病毒剂包括核苷类似物，如更昔洛韦，可抑制病毒复制。方法是将治疗有效量的诱导剂与抗病毒剂一起施用，以消灭受病毒感染的细胞。可治疗的病毒感染包括疱疹病毒感染，如卡波济氏相关疱疹病毒和 Epstein-Barr 病毒、HIV 感染和 HTLV 感染。这些组合物和方法对增殖细胞中的表观感染和潜伏感染特别有效。本发明还涉及向患者脉冲式施用组合物的新方法，用于治疗和预防细胞增殖性疾病，包括细胞减少症等缺陷和病毒诱发的肿瘤等恶性肿瘤、其他形式的肿瘤以及用于造血移植的细胞扩增。
• Compositions and administration of compositions for the treatment of blood disorders
  申请人：Susan Perrine

  公开号：US20010027215A1

  公开（公告）日：2001-10-04

  The invention relates to novel compositions and to methods for the pulsed administration of compositions to a patient or to cells in vitro for the treatment of human blood disorders. Compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia, blood loss, and other blood disorders. The invention also relates to methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies and for expansion of cells for hematopoietic transplantation. Pulsed administration has been shown to be more effective than continuous therapy in patients tested.

  本发明涉及新型组合物以及向患者或体外细胞脉冲施用组合物治疗人类血液疾病的方法。组合物含有刺激胎儿血红蛋白表达和/或刺激患者体内和体外红细胞、白细胞和血小板增殖的化合物，用于体内造血重建。这些方法可用于治疗或预防与贫血、镰状细胞病、地中海贫血、失血和其他血液疾病有关的症状。本发明还涉及向患者脉冲式施用组合物的方法，用于治疗和预防细胞增殖性疾病，包括细胞减少症和恶性肿瘤等缺陷，以及用于造血移植的细胞扩增。在测试的患者中，脉冲给药比连续治疗更有效。
• Compositions and methods for the treatment of cystic fibrosis
  申请人：——

  公开号：US20010034367A1

  公开（公告）日：2001-10-25

  The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.

  本发明涉及新型药物组合物，其中含有可用于治疗和预防囊性纤维化以及预防该疾病症状和体征的化学制剂。令人惊讶的是，这些药物组合物在治疗与囊性纤维化有关的疾病（包括造血功能障碍）方面取得了成功。本发明的许多组合物在以脉冲方式给患者用药时效果更好。脉冲疗法并不是在一段时间内不连续地给予相同量的组合物，而是包括以减少的频率或减少的剂量给予相同剂量的组合物。
• COMPOSITIONS COMPRISING AN INDUCING AGENT AND AN ANTI-VIRAL AGENT FOR THE TREATMENT OF BLOOD, VIRAL AND CELLULAR DISORDERS
  申请人：Perrine, Susan P.

  公开号：EP0969869A2

  公开（公告）日：2000-01-12